—
Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy.Get Sample Report @ https://www.wiseguyreports.com/sample-request/740555-burkitt-lymphoma-pipeline-review-h2-2016
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Burkitt Lymphoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkitt Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Burkitt Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 13 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Burkitt Lymphoma.
Burkitt Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Burkitt Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkitt Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkitt Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkitt Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkitt Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkitt Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Burkitt Lymphoma Overview 8
Therapeutics Development 9
Pipeline Products for Burkitt Lymphoma - Overview 9
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 10
Burkitt Lymphoma - Therapeutics under Development by Companies 11
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 13
Burkitt Lymphoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Burkitt Lymphoma - Products under Development by Companies 16
Burkitt Lymphoma - Products under Investigation by Universities/Institutes 17
Burkitt Lymphoma - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Arvinas, Inc. 19
bluebird bio, Inc. 20
Boehringer Ingelheim GmbH 21
Constellation Pharmaceuticals, Inc. 22
Immunomedics, Inc. 23
Karyopharm Therapeutics, Inc. 24
Millennium Pharmaceuticals Inc 25
Patrys Limited 26
Seattle Genetics, Inc. 27
Takeda Pharmaceutical Company Limited 28
Theravectys SA 29
Burkitt Lymphoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
19-3s - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
20-3s - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
alisertib - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ARV-825 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
bb-2121 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Cellular Immunotherapy to Target CD19 for ALL - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
denintuzumab mafodotin - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
E1-3s - Drug Profile 54
Product Description 54
Access Report @ https://www.wiseguyreports.com/reports/740555-burkitt-lymphoma-pipeline-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 146572
Google
RSS